(Total Views: 1226)
Posted On: 06/18/2022 4:44:31 PM
Post# of 155893
dr misiu most recent post "What happening with Leronlimab mid of 2022 .".
misiu143
What happening with Leronlimab mid of 2022 ..
— Combo HIV study results , 81% efficacy without one serious side effect .
When other 2 approved drugs for MDR patients are ,
Maraviroc with 45% efficacy and Black Box warning for liver injury ,
Ibalizumab 43% efficacy with some serious side effects , and every 2 weeks IV treatment
Capsid inhibitor coming , but will it be effective also in liver problems with this patients , or with increase number of malignancy we see in this patients , or HIV dementia or generally severe inflammation we see in HIV positive patients ..??
Leronlimab address each of this condition , studies are ongoing .
Dr Sacha just received almost 1 mill doll grant for a study of leronlimab and functional cure of HIV..
—Covid , excellent results showing when Leronlimab is I the system ,
82% mortality benefit ABOVE all the SOC drugs in critical patients ...
Excellent results observed in Long Covid during the study with Leronlimab . Peer Review paper published couple of months ago .
— cancers research showing big effects of CCR5 inhibitors on reducing cancers , our breast study showing already longer survival then with Gilead drug , Trodelvy , and without all this serious side effects..
Our patient with pancreatic cancer and urinary bladder , in patients without options doing well .
MD Anderson most probably finishing by now study with check point inhibitors , expecting very good results ,, study with CAR-T treatment going on in Boston . Here expected improvement in cancer but also eliminating or reducing severe side effects of CAR-T treatment .. Cytokine Release Syndrome .
Study with glioblastoma being done in NYC .
— NASH results very encouraging , after 14 weeks reduction of fatty deposits , and fibro - inflammation .
Study accepted , and will be presented by an international expert during prestigious international conference ..
— more and more studies done on CCR5 and neuroinflammation , diseases like Alz , Parkinson , MS , stroke etc .
Pre-clinical study for Alz is being done in London , England .
All this diseases and possibilities are hard to believe , and all this without one serious side effect ..
All imo
GLTA longs ..
misiu143
What happening with Leronlimab mid of 2022 ..
— Combo HIV study results , 81% efficacy without one serious side effect .
When other 2 approved drugs for MDR patients are ,
Maraviroc with 45% efficacy and Black Box warning for liver injury ,
Ibalizumab 43% efficacy with some serious side effects , and every 2 weeks IV treatment
Capsid inhibitor coming , but will it be effective also in liver problems with this patients , or with increase number of malignancy we see in this patients , or HIV dementia or generally severe inflammation we see in HIV positive patients ..??
Leronlimab address each of this condition , studies are ongoing .
Dr Sacha just received almost 1 mill doll grant for a study of leronlimab and functional cure of HIV..
—Covid , excellent results showing when Leronlimab is I the system ,
82% mortality benefit ABOVE all the SOC drugs in critical patients ...
Excellent results observed in Long Covid during the study with Leronlimab . Peer Review paper published couple of months ago .
— cancers research showing big effects of CCR5 inhibitors on reducing cancers , our breast study showing already longer survival then with Gilead drug , Trodelvy , and without all this serious side effects..
Our patient with pancreatic cancer and urinary bladder , in patients without options doing well .
MD Anderson most probably finishing by now study with check point inhibitors , expecting very good results ,, study with CAR-T treatment going on in Boston . Here expected improvement in cancer but also eliminating or reducing severe side effects of CAR-T treatment .. Cytokine Release Syndrome .
Study with glioblastoma being done in NYC .
— NASH results very encouraging , after 14 weeks reduction of fatty deposits , and fibro - inflammation .
Study accepted , and will be presented by an international expert during prestigious international conference ..
— more and more studies done on CCR5 and neuroinflammation , diseases like Alz , Parkinson , MS , stroke etc .
Pre-clinical study for Alz is being done in London , England .
All this diseases and possibilities are hard to believe , and all this without one serious side effect ..
All imo
GLTA longs ..
(6)
(0)
